What Has Been The Evolution of the Interleukin Inhibitors Market in Recent Years?
The interleukin inhibitors market has seen considerable growth due to a variety of factors.
• The market size of interleukin inhibitors has seen a swift increase in the recent past. Its growth is predicted to rise from a value of $42.93 billion in 2024 to $49.84 billion in 2025, reflecting a compound annual growth rate (CAGR) of 16.1%.
The historic period's growth can be linked to various factors such as an increased occurrence of autoimmune diseases, a heightened awareness of interleukin inhibitors, a rising demand for personalized medicine, an expanding elderly population, and a growing interest in biosimilars.
What Are the Future Growth Projections for the Interleukin Inhibitors Market?
The interleukin inhibitors market is expected to maintain its strong growth trajectory in upcoming years.
• The market for interleukin inhibitors is projected to experience significant expansion in the coming years, eventually reaching a value of $96.66 billion by 2029 with a compound annual growth rate (CAGR) of 18.0%.
This projected growth for the forecast period is due to several factors such as developing therapeutic indications, an increasing aging populace worldwide, the introduction of immunotherapy combinations, and a surge in research and development investments. Throughout the forecast period, leading trends would include oral interleukin inhibitors, advanced generation treatments, indications for children, extended access, and care geared towards the patient.
What Are The Core Factors Supporting Growth In The Interleukin Inhibitors Market?
The interleukin inhibitors market will be propelled by the rising count of experimental drugs for inflammation-related conditions like psoriasis, arthritis, and inflammatory bowel disease. Interleukin inhibitors aid in reducing inflammation-inducing cytokine activities, triggering innate immune reactions to protect the host from damage and to retain normal tissue balance. There are currently 48 molecules being investigated for the management of inflammatory diseases such as psoriasis and psoriatic arthritis. Of these, 20 molecules are in Phase III clinical trials. These increasing numbers of pipeline drugs are predicted to steer the growth of the interleukin inhibitors market upon their approval.
What Are The Major Segments Within The Global Interleukin Inhibitors Market?
The interleukin inhibitors market covered in this report is segmented –
1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6, Other Types
2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By IL-17: Secukinumab, Ixekizumab, Brodalumab
2) By IL-23: Ustekinumab, Guselkumab, Tildrakizumab
3) By IL-1: Anakinra, Canakinumab
4) By IL-5: Mepolizumab, Reslizumab, Benralizumab
5) By IL-6: Tocilizumab, Sarilumab
6) By Other Types: Other Interleukin Inhibitors
Pre-Book The Interleukin Inhibitors Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Interleukin Inhibitors Market?
The expiry of patents for biologic drugs opens up avenues for cheaper substitute drugs, known as biosimilars. Top businesses in the interleukin sector are channeling their efforts towards biosimilar development for interleukin inhibitors. Examples include the development of biosimilars for IL inhibitors like canakinumab (Ilaris), ustekinumab (Stelara), tocilizumab (Actemra), and secukinumab (Cosentyx) by Mabpharm, NeuClone Pharmaceuticals Ltd., Gedeon Richter, and Bio-Thera Solutions respectively. Despite the clear clinical advantages of biologics in treating psoriasis and other autoimmune diseases, many patients are not administered this treatment, with limited access to treatment often attributed to cost constraints. This, along with fast-paced advancements in biotechnology and analytical sciences ensuring biosimilars equivalency with biological drugs, fuels the biosimilars trend.
Who Are the Key Players In The Interleukin Inhibitors Market?
Major companies operating in the interleukin inhibitors market include:
• Sanofi S.A.
• GlaxoSmithKline plc
• Novartis International AG
• Johnson & Johnson Services Inc.
• F. Hoffmann-La Roche Ltd.
• Eli Lilly and Company
• AstraZeneca plc
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• Bausch Health Companies Inc.
• AbbVie Inc.
• Sun Pharmaceutical Industries Limited
• Boehringer Ingelheim International GmbH
• Janssen Biotech Inc.
• Ortho Dermatologics
• Amgen Inc.
• Celgene Corporation
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Merck & Co. Inc.
• Takeda Pharmaceutical Company Limited
• Biogen Inc.
• Vertex Pharmaceuticals Incorporated
• Incyte Corporation
• Seattle Genetics Inc.
• Karyopharm Therapeutics Inc.
• Kyowa Kirin Co Ltd.
• Astellas Pharma Inc.
• Ipsen Biopharmaceuticals Inc.
What Is The Most Dominant Region In The Interleukin Inhibitors Market?
North America was the largest region in the interleukin inhibitors market in 2024. The regions covered in the interleukin inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
